Interim report
Page 1
Marksans Pharma Ltd. 11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara, Andheri (W), Mumbai - 400 053 Tel.: +91 22 4001 2000 E-mail: companysecretary@marksanspharma.com www.marksanspharma.com Date: August 12, 2026 BSE Limited National Stock Exchange of India Limited Corporate Relation Department Listing Department Phiroze Jeejeebhoy Towers, Exchange Plaza, C-1, Block-G, Dalal Street, Bandra-Kurla Complex, Mumbai - 400001. Bandra (East), Mumbai - 400051. Scrip Code: 524404 Symbol: MARKSANS Sub: Outcome of Board Meeting Dear Sir/Madam, Pursuant to Regulation 33 and Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirement s) Regulations, 2015 (“Listing Regulations”) and other regulations, if ap plicable, we enclose herewith the Unaudited Financial Results (Consolidated and Standalone) of the Company for the quarter ended June 30, 2026 approved by the Board of Directors of the Company at its Meeting held today i.e. August 12, 2026 along with Limited Review Reports thereon. Pursuant to Regulation 33 of the Listing Regulations as amended, we hereby declare that M/s. MSKA & Associates LLP, Chartered Accountants, the Statutory Auditors of the Company have submitted the Limited Review Reports for Unaudited Financial Results (Consolidated and Standalone) of the Company for the quarter ended June 30, 2026 with an unmodified opinion. The aforesaid information is also available on the website of the Company at http://www.marksanspharma.com/quarterly-results.html The meeting commenced at 10:50 a.m. and concluded at 12:10 p.m. We request you to note the aforesaid in your records. Thanking You, Yours faithfully, For Marksans Pharma Limited Harshavardhan Panigrahi Company Secretary Encl. As Above
Page 2
MS K A & ASSOCiateS LLP :(?2. Floor 6, Raheja Titanium (Formerly known as M S K A & Associates) Westem Express Highway, Geetanjali Railway Colony, Ram Nagar, Goregaon (E) Chartered Accountants Mumbai 400063, INDIA Tel: +91 22 6974 0200 Independent Auditor’s Review Report on Standalone unaudited financial results of Marksans Pharma Limited for the quarter pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. To The Board of Directors of Marksans Pharma Limited 1. We have reviewed the accompanying statement of standalone unaudited financial results of Marksans Pharma Limited (hereinafter referred to as ‘the Company’) for the quarter ended 30 June 2026 (‘the Statement’) attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (‘the Regulations’). 2. This Statement, which is the responsibility of the Company’s Management and has been approved by the Company’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 ‘Interim Financial Reporting’, prescribed under Section 133 of the Companies Act, 2013 (‘the Act’) read with relevant rules issued thereunder (‘Ind AS 34’) and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, “Review of Interim Financial Information Performed by the Independent Auditor of the Entity” issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. 4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement. For M'S K A & Associates LLP (Formerly known as M S K A & Associates) Chartered Accountants ICAI Firm Registration No.105047W/W101187 i Nitin Tiwari Partner Membership No.:118894 UDIN: 2611 R394 RE THBI 3236 Place: Mumbai Date:12 August 2026 Registered Office: 602, Raheja Titanium, Western Express Highway, Goregaon (East), Mumbai-400063, Maharashtra, India Tel: +9122 6974 0200 | LLPIN: ACT-3789 Ahmedabad | Bengaluru | Chandigarh | Chennai | Coimbatore | Goa | Gurugram | Hyderabad | Kochi | Kolkata | Pune vwrw.mska,in
Page 3
MARKSANS PHARMA LIMITED CIN: L24110MH1992PLC086364 Registered Office: 11th Floor, Grandeur, Telephone No.: 022-4001 2000, Website: Veera Desal Extension Road, Oshiwara, Andher! [West], Mumbal-400053 ‘www.marksanspharma.com, E-mail: companysecretary@marksanspharma.com STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2026 Z in million except per equity share data) QUARTER ENDED YEAR ENDED | 30 June 2026 | 31 March 2026 | 30 June 2025 | 31 Mar 2026 sr. (AUDITED) No. PARTICULARS (UNAUDITED) (Refor Note 3) {UNAUDITED) | (AUDITED) 1 [Revenue from operations. 3,211.87 3,615.73 -+ 3,197.34 13,414.76 2 |Other income, net (Refer note 5) 174.70 274.75 20.10 1.035.33 3 [Total Income (1+2) 3,386.57 3,890.48 3,217.44 14,450.09 Expenses A |Cost of malerials consumed 1.416.43 1,594.82 1,452.77 6,024.27 B |Purchase of stock-in-trade 180.26 13259 227.98 730.62 ¢ [Changes ininventories of finished goods, work-in-progress and stock-in-trade (18.23) 25.84 (32.91) 32.95 D [Employee benefits expense 317.75 32015 279.04 121977 E |Finance costs 3.40 3.53 3.02 13.27 F |Depreciation and amortisation expense 87.76 87.56 81.88 342,30 G |Other expenses 494.62 473.41 569.92 2,171.48 4 |Total Expenses 2,481.99 2,646.90 2,581.70 10,534.66 5 |Profit Before Tax (3-4) 904.58 1,243.58 635.74 3,81543 | Tax Expense: (2) Current tax 213.90 301.08 14538 851.21 (b) Current tax for earlier period (0.10) - - 11.70 (c) Deferred tax 0.41 2327 9.80 45.54 6 |Total Tax Expense 214.21 324.35 155.18 908.45 7 |Profit Aftor Tax (5-6) 690.37 919.23 480.56 3,006.98 Other Comprehensive Income ltems that will not be reclassified to profit or loss. [Remeasurements of the net defined benefit plans 3.48 344 {1.01)] 13.91 Tax on above (0.88)] (0.87) 025 (3.50) 8 |Other Comprehensive Income 2.60 257 (0.76)| 10.41 9 |Total Comprehensive Income (7+8) 692,97 921.80 479.80 3,017.38 10 |Paid up Equity Share Capital (face value 21 each fully paid) 453.16 453.16 453.16 453.16 11 |Other equity 16,069.94 12 |Eamings per equity share of 21 each* Basic| 1.52 2,03 1.06 6.64 Diluted| 152 203 1.06 6.63 *EPS s not annualised for the quarter ended 30 June 2025, 31 March 2026 and 30 Juma 2075 y i
Page 4
MARKSANS PHARMA LIMITED NOTES TO STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2026 1 The standalone unaudited financial results of the Company for the quarter ended 30 June 2026 were reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 12 August 2026, The Statutory Auditors of the Company have carried out a limited review of the above results in terms of Regulation 33 of the SEBI (Listing and Disclosure Requirements) Regulations, 2015 (the Regulations), as amended and expressed an unmodified conclusion, The standalone unaudited financial results of the Company have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 ‘Interim Financial Reporting’, prescribed under Section 133 of the Companies Act, 2013 (‘the Act’) read with relevant rules issued thereunder and other recognised accounting principles generally accepted in India and in terms of the Regulations, The figures for the quarter ended 31 March 2026 represents the derived figures between the audited figures in respect of full financial year ended 31 March 2026 and the unaudited published year-to-date figures upto 31 December 2025, being the date of the end of the third quarter of the financial year which were subjected to limited review by the statutory auditor of the Company, The Company operates in one reportable business segment namely ‘Pharmaceuticals’ as per Ind AS 108 on ‘Operating Segments. Other income net includes net gain on foreign exchange differences amounting to Rs. 104.78 millions for the quarter ended 30 June 2026 (31 March 2026: net gain of Rs. 219.14 miltions, 30 June 2025: net loss of Rs. 37.73 millions, year ended 31 March 2026: net gain of Rs. 474,26 millions). ) During the current quarter, the Company has acquired 100% share capital of QUiniQ B.V., a company based in Netherlands, for a consideration of EUR 7.50 Miltion. QUiniQ B.V. specializes in bringing innovative healthcare solutions to the Dutch market through the marketing and distribution of Pprescription medicines and medical devices. Subsequent to the quarter ended 30 June 2026, the Company entered into a definitive agreement to acquire 100% of the share capital of ABCnow GmbH, a Germany-based pharmaceutical company with frontend sales, marketing, and distribution capabilities across German healthcare market, for a cash consideration of EUR 1.10 Million. The acquisition was subsequently completed, following which ABCnow GmbH became a wholly owned subsidiary of the Company. During the quarter ended 30 June 2026, the company granted 300,000 stock options under the Marksans Employees Stock Option Scheme 2024 to eligible employees of the Company and its subsidiary companies. Each stock option is exercisable into one equity share of the Company having a face value of 31 each. The above standalone unaudited financials results are available on the Company's website (www.marksanspharma.com) and stock exchanges websites, BSE {(www.bseindia.com) and NSE (www.nseindia.com), where the Company are listed, DIN: 00020983 Date : 12 August 2026 Place: Mumbai www.marksanspharma.com
Page 5
M S K A & ASSOCiateS LLP :‘?z, Floor 6, Raheja Titanium (Formerly known as M S K A & Associates) Western Express Highway, Geetanjali Railway Colony, Ram Nagar, Goregaon (E] Chartered Accountants Mumbat 400063, INDIA — geon () Tel: +91 22 6974 0200 Independent Auditor’s Review Report on consolidated unaudited financial results of Marksans Pharma Limited for the quarter pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended To the Board of Directors of Marksans Pharma Limited 1. We have reviewed the accompanying Statement of consolidated unaudited financial results of Marksans Pharma Limited hereinafter referred to as ‘the Holding Company’), its subsidiaries, (the Holding Company and its subsidiaries together referred to as the ‘Group’) for the quarter ended 30 June 2026 (‘the Statement’) attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (‘the Regulations’). 2. This Statement, which is the responsibility of the Holding Company’s Management and approved by the Holding Company’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 ‘Interim Financial Reporting’ prescribed under Section 133 of the Companies Act, 2013 (‘the Act’) read with relevant rules issued thereunder (‘Ind AS 34’) and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, ‘Review of Interim Financial Information Performed by the Independent Auditor of the Entity’ issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying anatytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33 (8) of the Regulations, to the extent applicable. 4. This Statement includes the results of the Holding Company and the following entities: Sr. Name of the Entity Relationship with the Holding Company No 1 Marksans Pharma (UK) Limited | Wholly owned subsidiary 2 Relonchem Limited Wholly owned subsidiary of Marksans Pharma (UK) Limited 3 Marksans Holdings Limited Wholly owned subsidiary of Marksans Pharma (UK) Limited 4 Bell, Sons and Co. (Druggists) Limited Wholly owned subsidiary of Marksans Holdings Limited Registered Office: 602, Raheja Titanium, Western Express Highway, Goregaon (East), Mumbai-400063, Maharashtra, India Tel: +91 22 6974 0200 | LLPIN: ACT-3789 Bengaluru | Chandigarh | Chennai | Coimbatore | Goa | Gurugram | Hyderabad | Kochi | Kolkata | Pune www.mska.in
Page 6
MSKA & Associates LLP (Formerly known as M S K A & Associates) Chartered Accountants Sr. No Name of the Entity Relationship with the Holding Company 5 Marksans Pharma Inc. Wholly owned subsidiary 6 Time-Cap Laboratories Inc. Wholly owned subsidiary of Marksans Pharma Inc. 7 Marise Ann Inc. Wholly owned subsidiary of Marksans Pharma Inc. 8 Custom Coating Inc. Wholly owned subsidiary of Time-Cap Laboratories Inc. 9 Marksans Realty LLC Wholly owned subsidiary of Time-Cap Laboratories Inc. 10 | Nova Pharmaceuticals Australasia Pty Ltd Subsidiary (60% Holding) " Nova Pharmaceuticals Limited Wholly owned subsidiary of Nova Pharmaceuticals Australasia Pty Ltd 12 | Access Healthcare for Medical Products L.L.C. Wholly owned subsidiary 13 Marksans Pharma GmbH Wholly owned subsidiary 14 Marksans Pharma (Europe) . Limited, Ireland Wholly owned subsidiary 15 | Marksans (Canada), Inc. Wholly owned subsidiary 16 QliniQ B.V. Wholly owned subsidiary w.e.f. 1 April 2026 5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement. 6. The Statement includes the financial information of seven subsidiaries which have not been reviewed by their auditors, whose interim financial information, before giving effect to the consolidation adjustments, reflects total revenue of Rs. 1,305.28 million, total net profit after tax of Rs. 95.13 million and total comprehensive income of Rs. 95.13 million for the quarter ended 30 June 2026, as considered in the Statement. These interim financial information have been furnished to us by the Management and our conclusion on the Statement in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on such management prepared unaudited interim financial information. According to the Registered Office: 602, Raheja Titanium, Western Express Highway, Goregaon (East), Mumbai-400063, Maharashtra, India Tel: +91 22 6974 0200 | LLPIN: ACT-3783 Bengaluru | Chandigarh | Chennai | Coimbatore | Goa | Gurugram | Hyderabad | Kochi | Kolkata | Mumbai | Pune wuww.mskain
Page 7
MSKA & Associates LLP (Formerly known as M S K A & Associates) Chartered Accountants information and explanations given to us by the Management, these interim financial information are not material to the Group. Our conclusion is not modified in respect of the above matter with respect to our reliance on the financial information certified by the management. For M'S K A & Associates LLP (Formerly known as M S K A & Associates) Chartered Accountants ICAI Firm Registration No.105047W/W101187 mvafl";— Nitin Tiwari Partner Membership No.: 118894 L UDIN: 26 1R RILOLZOU N 5o Place: Mumbai Date: 12 August 2026 Registered Office: 602, Raheja Titanium, Western Express Highway, Goregaon (East), Mumbai-400063, Maharashtra, India Tel: +9122 6974 0200 | LLPIN: ACT-3789 Ahmedabad | Bengaluru | Chandigarh | Chennai | Coimbatore | Goa | Gurugram | Hyderabad | Kochi | Kolkata | Mumbai | Pune www.mska.in
Page 8
MARKSANS PHARMA LIMITED CiN: L24110MH1992PLC066364 Registered Office: 11th Flaor, Grandeur, Veera Desal Extenslon Road, Oshiwara, Andheri [West], Mumbal-400053 Telephone No.: 022-4001 2000, Website: www.marksanspharma.com, E-mal: companysecretary@marksanspharma,com STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2026 (% In million except per equity share data) QUARTER ENDED [YEAR ENDED 30 June 2026 | 31 March 2026 ] 30 June 2025 | 31 Mar 2026 sr. (AUDITED) oy PARTICULARS (UNAUDITED) | o Nore 3)| (UNAUDITED) | (AuDITED) 1 [Revenue from operations 8407.96 8561.14 6,199.89 20,500.38 2 (Other income, net (Refer note 5) 25404 35174 56.41 82533 3 |Total Income (1+2) 8,662.00 8912.88 6,256.30 30,334.71 Expenses. A |Cost of materials consumed 2206.69 2649.72 1,926.94 592,08 B [Purchase of stock-In-trade 1384.49 1,498.11 1715.47 4,544.88 ¢ [Changes in inventories of finished goods, work-In-progress and stock-in-trade (156.52) (241.30)( - (1,024.29) (1,364.17) D |Employee benefits expense 1,142.94 1.067.56 083,85 4209.34 € |Finance costs 70.04 63.10 60.65 241.25 F | Depreciation and amortisation expense 248.64 24287 231.01 986.32 G |Other expenses 1.700.01 1,632.84 1,596.69 6519.46 4 |Total Expenses 6,596.29 6.912.90 5,490.32 24,729.16 5 [Profit Before Tax (34) 2,065.71 1,999.98 765.98 560555 Tax Expense: (3) Current tax 518.94 555.49 196.08 1499.64 (b) Current tax for earlier period (©.10) 2017 - 30.34 () Deferred tax (47.20) (66.00) (12.12) (125.07) 6 [Total Tax Expense 471.64 509.66 183.96 1,404.91 7 [Profit After Tax (5-6) 1,594.07 1,490.32 582.02 4,200.64 Other Comprehensive Income tems that will not be reclassified to profit or loss. (Remeasurements of the net defined benefit plans 348 344 (1.01) 1391 [Tax on above (0.88) (087) 025 (3.50) tems that will be reclassified to profit o loss. Foreign currency translation reserve (net) 167.64 536,83 666,05 1,751.07 8 |Other Comprehensive Income 170.24 539.40 665.29 1,761.48 9 [Total Comprenensive Income (7+8) 1,764.31 20029.72 1,247.31 5,962.12 [Net Profit attributable to:- [Owners of the Company 157167 1,481.29 58317 4,178.00 [Non-Controlling interests 2240 203 (1.15) 2164 Other Comprehensiva Income attributable to:- |Owners of the Company 166.90 51864 653.03 171250 Non-Controling interests 334 2076 12.28 48.89 Total Comprehensive Income attributable to:- Owners of the Company 173857 1,999.93 1.236.20 5.891.59 [Non-Controlling interests 2574 2979 111 7053 10 [Paid up Equity Share Capita (face value €1 each fully paid) 453.16 45316 453.18 453.16 11 [Other equity 2077840 12 |Earnings per equity share of 21 each® Basic| 347 327 Dilute| 347 327 *EPS s not annualised or the quarter ended 30 June 2026, 37 March 2026 8nd 30 Jons 207
Page 9
MARKSANS PHARMA LIMITED NOTES TO CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2026 1 The consolidated unaudited financiat results of the Company for the Quarter ended 30 June 2026 were reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 12 August 2026. The Statutory Auditors of the Company have carried out a limited review of the above results in terms of Regulation 33 of the SEBI (Listing and Disclosure Requirements) Regulations, 2015 (the Regulations'), as amended and expressed an unmodified conclusion, 2 The consolidated unaudited financial results of the Company have been Pprepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 ‘Interim Financial Reporting’, prescribed under Section 133 of the Companies Act, 2013 (‘the Act’) read with relevant rules issued thereunder and other recognised accounting principles generally accepted in India and in terms of the Regulations. 3 The figures for the quarter ended 31 March 2026 represents the derived figures between the audited figures in respect of full financial year ended 31 March 2026 and the unaudited Published year-to-date figures upto 31 December 2025, 4 The Group has a single business segment ‘Pharmaceuticals' as per Ind AS 108 on ‘Operating Segments. 5 Other income net includes net gain on foreign exchange differences amounting to Rs. 120.01 miltions for the quarter ended 30 June 2026 (31 March 2026: net gain of Rs. 247.99 millions, 30 June 2025: net loss of Rs. 38.93 millions, year ended 31 March 2026: net gain of Rs. 500.95 ‘millions). 6 During the current quarter, the Company has acquired 100% share capital of QliniQ B.V., a company based in Netherlands, for a consideration of EUR 7.50 Million. QliniQ B.V. specializes in bringing innovative healthcare solutions to the Dutch market through the marketing and distribution of Prescription medicines and medical devices. QliniQ B.V. s a subsidiary of the company w.e.f. 1 April 2026, As per Ind AS 103 on ‘Business Combinations’, purchase consideration has been allocated on a provisional basis, pending final determination of the fair value of the acquired assets and liabilities. 7 Subsequent to the quarter ended 30 June 2026, the Company entered into a definitive agreement to acquire 100% of the share capital of ABCnow GmbH, a Germany-based pharmaceutical company with frontend sales, marketing, and distribution capabilities across German healthcare market, for a cash consideration of EUR 1.10 Million, The acquisition was subsequently completed, following which ABCnow GmbH became a wholly owned subsidiary of the Company. 8 During the quarter ended 30 June 2026, the company granted 300,000 stock options under the Marksans Employees Stock Option Scheme 2024 to eligible employees of the Company and its subsidiary companies. Each stock option is exercisable into one equity share of the Company having a face value of ¥1 each. 9 The above consolidated unaudited financials results are available on the Companys website (www.marksanspharma.com) and stock exchanges websites, BSE (www.bseindia.com) and NSE {www.nseindia.com), where the shares of the Company are listed. W Tk Saldanha Chairman & Managing Director DIN: 00020983 Date : 12 August 2026 Place: Mumbai www.marksanspharma.com